Jardiance 01
Chemical structure diagram of Empagliflozin, the active ingredient in JARDIANCE 10 mg film-coated oral tablets by A-S Medication Solutions.*
Jardiance Tablet, Film Coated
Product Images NDC 50090-4492
9 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-4492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Jardiance 02
A scatter plot displaying the geometric mean ratio with 90% confidence intervals for various drugs compared to empagliflozin alone. The chart lists antidiabetic drugs and other medications on the vertical axis and shows relative changes in AUC and Cmax values on the horizontal axis, ranging from 50 to 200 percent. Each point represents change relative to empagliflozin alone for both AUC and Cmax parameters.*
Jardiance 03
A forest plot chart showing the geometric mean ratio with 90% confidence intervals for the area under the curve (AUC) and maximum concentration (Cmax) of various drugs including antidiabetic drugs, oral contraceptives, and others. The x-axis ranges approximately from 50 to 150, with each drug listed on the y-axis alongside its dosage and frequency.*
Jardiance 04
This chart depicts the mean change from baseline in HbA1c percentage over 24 weeks for patients receiving placebo, Empagliflozin 10 mg, and Empagliflozin 25 mg. The x-axis represents time in weeks, and the y-axis shows HbA1c change percentage. Empagliflozin groups show a greater reduction in HbA1c compared to placebo, with error bars indicating variability around mean values.*
Jardiance 05
A line graph comparing mean percentage changes in HbA1c levels from baseline over 52 weeks between two treatments: Glimepiride plus Metformin (N=700) and Empagliflozin 25 mg plus Metformin (N=693). The graph shows HbA1c changes from baseline at weeks 4, 12, 28, 40, and 52, including mean and error bars for each treatment group at week 52, adjusted for baseline HbA1c, geographical region, and eGFR.*
Jardiance 06
A line graph comparing the percentage of patients with an event over 48 months between placebo and all empagliflozin groups. The x-axis represents months, and the y-axis shows the percentage of patients with an event. The graph includes a table below with the number of subjects at risk for each group at different time points.*
Jardiance 07
A line graph comparing the percentage of patients with an event over 48 months between placebo and empagliflozin groups. The y-axis shows patients with event (%) up to 20%, and the x-axis shows time in months from 0 to 48. A table below lists the number of subjects at risk for each group at various time points.*
Jardiance 08
Label Image (Lbl500904492)
Label for JARDIANCE 10 mg film-coated tablets by A-S Medication Solutions. Each tablet contains 10 mg of Empagliflozin. The label indicates a package containing 90 tablets, with storage instructions to keep at 77 degrees Fahrenheit. It includes a QR code and bar code for dose package identification and other tracking information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
